Jin He

Jin He

Auto-generated profile, based on publicly available information

Jin He

MOE Key Laboratory for Cellular Dynamics, School of Life Sciences, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, Anhui, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Biomaterials
Verified
Journal Article
Closed access
HLHaiyan Li
Haiyan Li
JHJin He
Jin He
HYHongfei Yu
Hongfei Yu
CGColin R. Green
Colin R. Green
JCJiang Chang
Jiang Chang

22 February 2024 in Cell Reports
Verified
Journal Article
Open access
MWMingxing Wang
Mingxing Wang
LCLong Chen
Long Chen
JHJin He
Jin He
WXWenqiang Xia
Wenqiang Xia
ZYZihong Ye
Zihong Ye
JSJi She
Ji She
Antibody inhibitors of the interleukin-6 (IL-6) signaling pathway, such as tocilizumab and sarilumab, have been used to treat rheumatoid arthritis, chimeric antigen receptor T cell-induced cytokine storm, and severe COVID-19 pneumonia. Here, we solve the cryogenic electron microscopy structures of sarilumab and tocilizumab in complex with IL-6R to resolutions of 3.2 and 3.3 Å, respectively. These structures reveal that both tocilizumab and sarilumab bind to the D3 domain of IL-6R. The binding surfaces of the two antibodies largely overlap, but the detailed interactions are different. Functional studies of various mutants show results consistent with our structural analysis of the antibodies and IL-6R interactions. Structural comparisons with the IL-6/IL-6R/gp130 complex indicate that sarilumab and tocilizumab probably inhibit IL-6/IL-6R signaling by competing for the IL-6 binding site. In summary, this work reveals the antibody-blocking mechanism of the IL-6 signaling pathway and paves the way for future antibody discovery.